Bookmark and Share
1-(carboxymethylthio)tetradecane (CID 114924) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(13)
 
 
Inactive(256)
 
 
Inconclusive(41)
 
 
Unspecified(37)
 
 
Top Targets:
p450(9)
 
 
 
NR LBD TR(8)
 
 
 
7TM GPCR Srx(7)
 
 
 
PLN02808(6)
 
 
ANK(6)
 
 
 
BioAssay Types:
Confirmatory(266)
 
 
 
 
 
Literature(45)
 
 
 
 
Screening(11)
 
 
 
Summary(1)
 
 
BioActivity Types:
Potency(240)
 
 
 
 
 
IC50(1)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 288    Data Row: 347   Total Pages: 7   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID26753658]
Potency 10qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway [AID651778, Type: confirmatory]Peroxisome proliferator-activated receptor alpha [gi:3041727]
View
2
[SID90340854]
Potency 10qHTS Assay for Inhibitors of GCN5L2 [AID504327, Type: confirmatory]histone acetyltransferase KAT2A [Homo sapiens] [gi:153791535]
View
3
[SID90340854]
Potency 23.9341qHTS Validation Assay to Find Inhibitors of Pin1 [AID504536, Type: confirmatory]peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 [Homo sapiens] [gi:5453898]
View
4
[SID90340854]
Potency 25.1189Inhibitors of USP1/UAF1: Pilot qHTS [AID504865, Type: confirmatory]USP1 protein [Homo sapiens] [gi:118600387]
View
5
[SID26753658]
Potency 28.1838qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling [AID588536, Type: confirmatory]peroxisome proliferator activated receptor gamma [Homo sapiens] [gi:216409692]
View
6
[SID85231250]
Potency 31.6228qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails [AID488949, Type: confirmatory]M-phase phosphoprotein 8 [Homo sapiens] [gi:41055989]
View
7
[SID103456707]
IC50 43Concentration required for inhibition of lipid synthesis in primary cultures of rat hepatocytes [AID248137, Type: Literature]
View
8
[SID90340854]
Potency 50.1187qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails [AID488953, Type: confirmatory]chromobox protein homolog 1 [Homo sapiens] [gi:187960037]
View
9
[SID17405711]
HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors [AID694, Type: confirmatory]Estrogen receptor 1 [Homo sapiens] [gi:118764400]
View
10
[SID17405711]
HTS for BAP1 Enzyme inhibitors [AID436, Type: screening]Ubiquitin carboxyl-terminal hydrolase BAP1 [gi:68565074]
View
11
[SID103456707]
Activation of PPARalpha expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay [AID476931, Type: Literature]
View
12
[SID103456707]
Activation of PPARdelta expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay [AID476933, Type: Literature]
View
13
[SID103456707]
Activation of PPARgamma expressed in human MCF7 cells at 30 uM by luciferase reporter gene assay [AID476935, Type: Literature]
View
14
[SID26753658]
qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways [AID651838, Type: other]
View
15
[SID103456707]
Decrease in plasma cholesterol level in po dosed Wistar rat after 6 days [AID346092, Type: Literature]
View
16
[SID103456707]
Decrease in plasma triacylglycerol level in po dosed Wistar rat after 6 days [AID346093, Type: Literature]
View
17
[SID103456707]
Induction of PPAR-alpha-regulated HMG-CoA synthase activity in po dosed Wistar rat after 6 days [AID346098, Type: Literature]
View
18
[SID103456707]
Induction of PPAR-alpha-regulated fatty acyl-CoA oxidase activity in po dosed Wistar rat after 6 days [AID346099, Type: Literature]
View
19
[SID103456707]
Induction of PPAR-alpha-regulated CPT2 activity in po dosed Wistar rat after 6 days [AID346102, Type: Literature]
View
20
[SID103456707]
Increase in [1-14C]palmitoyl-CoA oxidation in po dosed Wistar rat liver homogenate after 6 days [AID346104, Type: Literature]
View
21
[SID103456707]
Plasma concentration in Wistar rat at 85 uM, po after 6 days [AID346106, Type: Literature]
View
22
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma saturated fatty acid level at 85 uM, po after 6 days [AID346107, Type: Literature]
View
23
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma MUFA level at 85 uM, po after 6 days [AID346108, Type: Literature]
View
24
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma PUFA level at 85 uM, po after 6 days [AID346109, Type: Literature]
View
25
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma 18;2, n-6 level at 85 uM, po after 6 days [AID346110, Type: Literature]
View
26
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma LCPUFA, n-6 level at 85 uM, po after 6 days [AID346111, Type: Literature]
View
27
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma LCn-6/18:2 level at 85 uM, po after 6 days [AID346112, Type: Literature]
View
28
[SID103456707]
Plasma concentration in Wistar rat at 250 uM, po after 6 days [AID346113, Type: Literature]
View
29
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma saturated fatty acid level at 250 uM, po after 6 days [AID346114, Type: Literature]
View
30
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma MUFA level at 250 uM, po after 6 days [AID346115, Type: Literature]
View
31
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma PUFA level at 250 uM, po after 6 days [AID346116, Type: Literature]
View
32
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma 18;2, n-6 level at 250 uM, po after 6 days [AID346117, Type: Literature]
View
33
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma LCPUFA, n-6 level at 250 uM, po after 6 days [AID346118, Type: Literature]
View
34
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in plasma LCn-6/18:2 level at 250 uM, po after 6 days [AID346119, Type: Literature]
View
35
[SID103456707]
Drug level in Wistar rat liver at 85 uM, po after 6 days [AID346120, Type: Literature]
View
36
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver saturated fatty acid level at 85 uM, po after 6 days [AID346121, Type: Literature]
View
37
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver MUFA level at 85 uM, po after 6 days [AID346122, Type: Literature]
View
38
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver PUFA level at 85 uM, po after 6 days [AID346123, Type: Literature]
View
39
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver 18;2, n-6 level at 85 uM, po after 6 days [AID346124, Type: Literature]
View
40
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver LCPUFA, n-6 level at 85 uM, po after 6 days [AID346125, Type: Literature]
View
41
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver LCn-6/18:2 level at 85 uM, po after 6 days [AID346126, Type: Literature]
View
42
[SID103456707]
Drug level in Wistar rat liver at 250 uM, po after 6 days [AID346127, Type: Literature]
View
43
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver saturated fatty acid level at 250 uM, po after 6 days [AID346128, Type: Literature]
View
44
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver MUFA level at 250 uM, po after 6 days [AID346129, Type: Literature]
View
45
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver PUFA level at 250 uM, po after 6 days [AID346130, Type: Literature]
View
46
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver 18;2, n-6 level at 250 uM, po after 6 days [AID346131, Type: Literature]
View
47
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver LCPUFA, n-6 level at 250 uM, po after 6 days [AID346132, Type: Literature]
View
48
[SID103456707]
Effect on fatty acid composition in Wistar rat assessed as change in liver LCn-6/18:2 level at 250 uM, po after 6 days [AID346133, Type: Literature]
View
49
[SID11111865]
Cytochrome panel assay with activity outcomes [AID1851, Type: other]
View
50
[SID50107077]
Potency qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding [AID2675, Type: confirmatory]muscleblind-like protein 1 isoform a [Homo sapiens] [gi:41281591]
View